CRYSTAL-STRUCTURES OF HIV-2 PROTEASE IN COMPLEX WITH INHIBITORS CONTAINING THE HYDROXYETHYLAMINE DIPEPTIDE ISOSTERE

被引:40
作者
TONG, L
PAV, S
MUI, S
LAMARRE, D
YOAKIM, C
BEAULIEU, P
ANDERSON, PC
机构
[1] BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT BIOCHEM,RIDGEFIELD,CT 06877
[2] BIO MEGA BOEHRINGER INGELHEIM RES INC,DEPT BIOCHEM,LAVAL,PQ H7S 2G5,CANADA
[3] BIO MEGA BOEHRINGER INGELHEIM RES INC,DEPT CHEM,LAVAL,PQ H7S 2G5,CANADA
关键词
AIDS; ASPARTIC PROTEASES; PEPTIDOMIMETIC INHIBITORS; RETROVIRUS;
D O I
10.1016/S0969-2126(01)00133-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: The HIV protease is essential for the life cycle of the virus and is an important target for the development of therapeutic treatments against AIDS. The structures of HIV protease in complex with different inhibitors have helped in understanding the interactions between inhibitors and the protease and in the design and optimization of HIV protease inhibitors. Results: We report here crystal structures at up to 1.7 Angstrom resolution of the homodimeric HIV-2 protease in complex with seven inhibitors containing the hydroxyethylamine dipeptide isostere. A novel dimethylphenoxyacetyl group that is present in some of these inhibitors is inserted between residues 48' and 49' in the flap of the protease and residues 29' and 30' (where a prime indicates a residue in the second monomer), which undergo a conformational change to accommodate the phenyl ring of the inhibitor. Conclusions: This study shows that besides the residues in the nap and residues 79-81 in the S-1 substrate-binding pocket which undergo conformational changes upon inhibitor binding, residues 29 and 30 can also adapt their conformation to fit certain inhibitors. Conformational flexibility of the HIV protease plays an important role in inhibitor binding.
引用
收藏
页码:33 / 40
页数:8
相关论文
共 22 条
[1]   PROTEIN DATA BANK - COMPUTER-BASED ARCHIVAL FILE FOR MACROMOLECULAR STRUCTURES [J].
BERNSTEIN, FC ;
KOETZLE, TF ;
WILLIAMS, GJB ;
MEYER, EF ;
BRICE, MD ;
RODGERS, JR ;
KENNARD, O ;
SHIMANOUCHI, T ;
TASUMI, M .
JOURNAL OF MOLECULAR BIOLOGY, 1977, 112 (03) :535-542
[2]  
BRUNGER AT, 1992, XPLOR MANUAL
[3]   COMPARATIVE-ANALYSIS OF THE SEQUENCES AND STRUCTURES OF HIV-1 AND HIV-2 PROTEASES [J].
GUSTCHINA, A ;
WEBER, IT .
PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1991, 10 (04) :325-339
[4]   INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C(2) SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE [J].
HOSUR, MV ;
BHAT, TN ;
KEMPF, DJ ;
BALDWIN, ET ;
LIU, BS ;
GULNIK, S ;
WIDEBURG, NE ;
NORBECK, DW ;
APPELT, K ;
ERICKSON, JW .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1994, 116 (03) :847-855
[5]   GRAPHICS MODEL-BUILDING AND REFINEMENT SYSTEM FOR MACROMOLECULES [J].
JONES, TA .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1978, 11 (AUG) :268-272
[6]   ACTIVE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE IS REQUIRED FOR VIRAL INFECTIVITY [J].
KOHL, NE ;
EMINI, EA ;
SCHLEIF, WA ;
DAVIS, LJ ;
HEIMBACH, JC ;
DIXON, RAF ;
SCOLNICK, EM ;
SIGAL, IS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4686-4690
[7]   NOVEL BINDING MODE OF HIGHLY POTENT HIV-PROTEINASE INHIBITORS INCORPORATING THE (R)-HYDROXYETHYLAMINE ISOSTERE [J].
KROHN, A ;
REDSHAW, S ;
RITCHIE, JC ;
GRAVES, BJ ;
HATADA, MH .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (11) :3340-3342
[8]   RATIONAL DESIGN OF POTENT, BIOAVAILABLE, NONPEPTIDE CYCLIC UREAS AS HIV PROTEASE INHIBITORS [J].
LAM, PYS ;
JADHAV, PK ;
EYERMANN, CJ ;
HODGE, CN ;
RU, Y ;
BACHELER, LT ;
MEEK, JL ;
OTTO, MJ ;
RAYNER, MM ;
WONG, YN ;
CHANG, CH ;
WEBER, PC ;
JACKSON, DA ;
SHARPE, TR ;
ERICKSONVIITANEN, S .
SCIENCE, 1994, 263 (5145) :380-384
[10]   MOLECULAR TARGETS FOR AIDS THERAPY [J].
MITSUYA, H ;
YARCHOAN, R ;
BRODER, S .
SCIENCE, 1990, 249 (4976) :1533-1544